Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2020

01-02-2020 | Diabetic Retinopathy | Review Article

The role of Müller cell glucocorticoid signaling in diabetic retinopathy

Authors: Farhad Ghaseminejad, Lew Kaplan, Anna M. Pfaller, Stefanie M. Hauck, Antje Grosche

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2020

Login to get access

Abstract

Diabetic retinopathy (DR) is a sight-threatening complication associated with the highly prevalent diabetes disorder. Both the microvascular damage and neurodegeneration detected in the retina caused by chronic hyperglycemia have brought special attention to Müller cells, the major macroglia of the retina that are responsible for retinal homeostasis. Given the role of glucocorticoid signaling in anti-inflammatory responses and the almost exclusive expression of glucocorticoid receptors (GRs) in retinal Müller cells, administration of corticosteroid agonists as a potential treatment option has been widely studied. Although these approaches have been moderately efficacious in treating or de-escalating DR pathomechanisms, there are various side effects and gaps of knowledge with regard to introducing exogenous glucocorticoids to the diseased retina. In this paper, we provide a review of the literature concerning the available evidence for the role of Müller cell glucocorticoid signaling in DR and we discuss previously investigated approaches in modulating this system as possible treatment options. Furthermore, we propose a novel alternative to the available choices of treatment by using gene therapy as a tool to regulate the expression of GR in retinal Müller cells. Upregulating GR expression allows for induced glucocorticoid signaling with more enduring effects compared to injection of agonists. Hence, repetitive injections would no longer be required. Lastly, side effects of glucocorticoid therapy such as glucocorticoid resistance of GR following chronic exposure to excess ligands or agonists can be avoided.
Literature
1.
Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733):2215–2222
2.
Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564PubMedPubMedCentral
3.
Lee R, Wong TY, Sabanayagam C (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vision 2(1):17PubMed
4.
Olivares AM, Althoff K, Chen GF et al (2017) Animal models of diabetic retinopathy. Curr Diabetes Rep 17(10):93
5.
Hammes HP (2018) Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia 61(1):29–38PubMed
6.
Tuomi T (2005) Type 1 and type 2 diabetes: what do they have in common? Diabetes. 54(suppl 2):S40–S45PubMed
7.
8.
Lachin JM, Genuth S, Nathan DM (2008) Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial—revisited. Diabetes 57(4):995–1001PubMed
9.
Zong H, Ward M, Stitt AW (2011) AGEs, RAGE, and diabetic retinopathy. Curr Diabetes Rep 11(4):244–252
10.
Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188PubMed
11.
12.
Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9(4):315–327PubMed
13.
Thornalley PJ (2003) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348PubMed
14.
Rabbani N, Xue M, Thornalley PJ (2016) Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj J 33(4):513–525PubMedPubMedCentral
15.
Hidmark A, Fleming T, Vittas S (2014) A new paradigm to understand and treat diabetic neuropathy. Exp Clin Endocrinol Diabetes 226(04):201–207
16.
Sachdeva R, Schlotterer A, Schumacher D (2018) TRPC proteins contribute to development of diabetic retinopathy and regulate glyoxalase 1 activity and methylglyoxal accumulation. Mol Metab 9:156–167PubMedPubMedCentral
17.
Malaguarnera L, Zorena K (2016) Neurodegeneration and neuroinflammation in diabetic retinopathy: potential approaches to delay neuronal loss. Curr Neuropharmacol 14(8):831–839PubMedPubMedCentral
18.
Reiter CE, Gardner TW (2003) Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog Retin Eye Res 22(4):545–562PubMed
19.
Barber AJ, Lieth E, Khin SA et al (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102(4):783–791PubMedPubMedCentral
20.
Fort PE, Losiewicz MK, Reiter CE et al (2011) Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS One 6(10):e26498PubMedPubMedCentral
21.
Duh EJ, Sun JK, Stitt AW (2017) Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI insight 2(14)
22.
Zhang X, Zeng H, Bao S et al (2014) Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 4(1):27PubMedPubMedCentral
23.
24.
Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 83(3):473–483PubMed
25.
26.
Robinson R, Barathi VA, Chaurasia SS (2012) Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 5(4):444–456PubMedPubMedCentral
27.
Reichenbach A, Bringmann A (2013) New functions of Müller cells. Glia. 61(5):651–678PubMed
28.
Coughlin BA, Feenstra DJ, Mohr S (2017) Müller cells and diabetic retinopathy. Vis Res 139:93–100
29.
Reichenbach A, Wurm A, Pannicke T et al (2007) Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 245(5):627–636PubMed
30.
Lieth E, Barber AJ, Xu B et al (1998) Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 47(5):815–820PubMed
31.
Kowluru RA, Engerman RL, Case GL et al (2001) Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 38(5):385–390PubMed
32.
Li Q, Puro DG (2002) Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci 43(9):3109–3116PubMed
33.
Eichler W, Kuhrt H, Hoffmann S et al (2000) VEGF release by retinal glia depends on both oxygen and glucose supply. Neuroreport. 11(16):3533–3537PubMed
34.
Pannicke T, Iandiev I, Wurm A et al (2006) Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes. 55(3):633–639PubMed
35.
Newman E, Reichenbach A (1996) The Müller cell: a functional element of the retina. Trends Neurosci 19(8):307–312PubMed
36.
Pannicke T, Iandiev I, Uckermann O et al (2004) A potassium channel-linked mechanism of glial cell swelling in the postischemic retina. Mol Cell Neurosci 26(4):493–502PubMed
37.
Iandiev I, Tenckhoff S, Pannicke T et al (2006) Differential regulation of Kir4. 1 and Kir2. 1 expression in the ischemic rat retina. Neurosci Lett 396(2):97–101PubMed
38.
Pannicke T, Uckermann O, Iandiev I et al (2005) Ocular inflammation alters swelling and membrane characteristics of rat Müller glial cells. J Neuroimmunol 161(1–2):145–154PubMed
39.
Krügel K, Wurm A, Pannicke T et al (2011) Involvement of oxidative stress and mitochondrial dysfunction in the osmotic swelling of retinal glial cells from diabetic rats. Exp Eye Res 92(1):87–93PubMed
40.
Wurm A, Iandiev I, Hollborn M et al (2008) Purinergic receptor activation inhibits osmotic glial cell swelling in the diabetic rat retina. Exp Eye Res 87(4):385–393PubMed
41.
Pazdro R, Burgess JR (2010) The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev 131(4):276–286PubMed
42.
Du Y, Sarthy VP, Kern TS (2004) Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Phys Regul Integr Comp Phys 287(4):R735–R741
43.
44.
Gallina D, Zelinka C, Fischer AJ (2014) Glucocorticoid receptors in the retina, Müller glia and the formation of Müller glia-derived progenitors. Development. 141(17):3340–3351PubMedPubMedCentral
45.
Schaaf MJ, Cidlowski JA (2002) Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83(1–5):37–48PubMed
46.
Zhang X, Wang N, Schachat AP et al (2014) Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med 14(3):376–384PubMed
47.
Yeager MP, Pioli PA, Guyre PM (2011) Cortisol exerts bi-phasic regulation of inflammation in humans. Dose-Response. 9(3):332–347PubMed
48.
Roy MS, Roy A, Brown S (1998) Increased urinary-free cortisol outputs in diabetic patients. J Diabetes Complicat 12(1):24–27PubMed
49.
Chiodini I, Adda G, Scillitani A et al (2007) Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30(1):83–88PubMed
50.
Erickson RL, Browne CA, Lucki I (2017) Hair corticosterone measurement in mouse models of type 1 and type 2 diabetes mellitus. Physiol Behav 178:166–171PubMedPubMedCentral
51.
Vandevyver S, Dejager L, Libert C (2014) Comprehensive overview of the structure and regulation of the glucocorticoid receptor. Endocr Rev 35(4):671–693PubMed
52.
Gallina D, Zelinka CP, Cebulla CM et al (2015) Activation of glucocorticoid receptors in Müller glia is protective to retinal neurons and suppresses microglial reactivity. Exp Neurol 273:114–125PubMedPubMedCentral
53.
Shen W, Lee SR, Araujo J et al (2014) Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Müller cell ablation. Glia. 62(7):1110–1124PubMed
54.
Brooks HL, Caballero S, Newell CK et al (2004) Vitreous kevels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 122(12):1801–1807PubMed
55.
Itakura H, Akiyama H, Hagimura N et al (2006) Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Müller cells. Graefes Arch Clin Exp Ophthalmol 244(2):226–231PubMed
56.
Shen W, Fruttiger M, Zhu L et al (2012) Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci 32(45):15715–15727PubMedPubMedCentral
57.
Sulaiman RS, Kadmiel M, Cidlowski JA (2018) Glucocorticoid receptor signaling in the eye. Steroids. 133:60–66PubMed
58.
Ramamoorthy S, Cidlowski JA (2016) Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin 42(1):15–31
59.
Ameyar M, Wisniewska M, Weitzman JB (2003) A role for AP-1 in apoptosis: the case for and against. Biochimie. 85(8):747–752PubMed
60.
Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20(21):6071–6083PubMedPubMedCentral
61.
Chinenov Y, Gupte R, Dobrovolna J et al (2012) Role of transcriptional coregulator GRIP1 in the anti-inflammatory actions of glucocorticoids. Proc Natl Acad Sci 109(29):11776–11781PubMed
62.
Nelson G, Wilde GJ, Spiller DG et al (2003) NF-κB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 116(12):2495–2503PubMed
63.
64.
Caldenhoven E, Liden J, Wissink S et al (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids. Mol Endocrinol 9(4):401–412PubMed
65.
Morikawa M, Derynck R, Miyazono K (2016) TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8(5):a021873PubMedPubMedCentral
66.
67.
Yafai Y, Iandiev I, Lange J et al (2014) Müller glial cells inhibit proliferation of retinal endothelial cells via TGF-β2 and Smad signaling. Glia. 62(9):1476–1485PubMed
68.
Gerhardinger C, Dagher Z, Sebastiani P et al (2009) The transforming growth factor-β pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes. 58(7):1659–1667PubMedPubMedCentral
69.
Song CZ, Tian X, Gelehrter TD (1999) Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci 96(21):11776–11781PubMed
70.
71.
Yun JH, Park SW, Kim KJ et al (2017) Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy. J Cell Physiol 232(5):1123–1134PubMed
72.
Langlais D, Couture C, Balsalobre A et al (2012) The Stat3/GR interaction code: predictive value of direct/indirect DNA recruitment for transcription outcome. Mol Cell 47(1):38–49PubMed
73.
Macosko EZ, Basu A, Satija R et al (2015) Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 161(5):1202–1214PubMedPubMedCentral
74.
Peng YR, Shekhar K, Yan W et al (2019) Molecular classification and comparative taxonomics of foveal and peripheral cells in primate retina. Cell. 176(5):1222–1237PubMed
75.
Mages K, Grassmann F, Jägle H et al (2019) The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia. J Neuroinflammation 16(1):43PubMedPubMedCentral
76.
Das A, Stroud S, Mehta A et al (2015) New treatments for diabetic retinopathy. Diabetes Obes Metab 17(3):219–230PubMed
77.
Fong DS, Girach A, Boney A (2007) Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 27(7):816–824PubMed
78.
Dugel PU, Bandello F, Loewenstein A (2015) Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol (Auckland, NZ) 9:1321
79.
80.
Van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 293(12):1509–1513PubMed
81.
Bainbridge JW, Smith AJ, Barker SS et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358(21):2231–2239PubMed
82.
Le Meur G, Lebranchu P, Billaud F et al (2018) Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis. Mol Ther 26(1):256–268PubMed
83.
Wang JH, Ling D, Tu L et al (2017) Gene therapy for diabetic retinopathy: are we ready to make the leap from bench to bedside? Pharmacol Ther 173:1–18PubMed
84.
Ideno J, Mizukami H, Kakehashi A et al (2007) Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 19(1):75–79PubMed
85.
Pechan P, Rubin H, Lukason M et al (2009) Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16(1):10PubMed
86.
Jiang J, Xia XB, Xu HZ et al (2009) Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1α and VEGF. J Cell Physiol 218(1):66–74PubMed
87.
Haurigot V, Villacampa P, Ribera A et al (2012) Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One 7(7):e41511PubMedPubMedCentral
88.
Shyong MP, Lee FL, Kuo PC et al (2007) Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis 13:133PubMedPubMedCentral
89.
Gong Y, Chang ZP, Ren RT et al (2012) Protective effects of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats. Cell Mol Neurobiol 32(3):467–475PubMed
90.
Ramírez M, Wu Z, Moreno-Carranza B et al (2011) Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF-and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci 52(12):8944–8950PubMed
91.
Metadata
Title
The role of Müller cell glucocorticoid signaling in diabetic retinopathy
Authors
Farhad Ghaseminejad
Lew Kaplan
Anna M. Pfaller
Stefanie M. Hauck
Antje Grosche
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-019-04521-w

Other articles of this Issue 2/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2020 Go to the issue

Pediatrics

The vascular densities of the macula and optic disc in normal eyes from children by optical coherence tomography angiography

Cataract

Comparing refractive outcomes of a standard industry toric IOL calculator using anterior corneal astigmatism and total corneal refractive power

Pediatrics

Risk factors associated with poor outcome after medial rectus resection for recurrent intermittent exotropia

Basic Science

SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice

Basic Science

Studies on retinal mechanisms possibly related to myopia inhibition by atropine in the chicken

Glaucoma

Clinical and ASOCT evaluations of ‘bleb-sparing epithelial exchange’ in paediatric and adult dysfunctional blebs over 5 years